SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 260 filers reported holding SAGE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,601 | -56.2% | 175 | 0.0% | 0.00% | – |
| Q2 2023 | $8,228 | +12.1% | 175 | 0.0% | 0.00% | – |
| Q1 2023 | $7,343 | +104800.0% | 175 | -5.4% | 0.00% | – |
| Q4 2022 | $7 | -99.9% | 185 | 0.0% | 0.00% | – |
| Q3 2022 | $7,000 | +40.0% | 185 | +5.7% | 0.00% | – |
| Q2 2022 | $5,000 | -16.7% | 175 | -9.8% | 0.00% | – |
| Q1 2022 | $6,000 | -14.3% | 194 | +10.9% | 0.00% | – |
| Q4 2021 | $7,000 | 0.0% | 175 | 0.0% | 0.00% | – |
| Q3 2021 | $7,000 | -30.0% | 175 | 0.0% | 0.00% | – |
| Q2 2021 | $10,000 | -23.1% | 175 | 0.0% | 0.00% | – |
| Q1 2021 | $13,000 | -13.3% | 175 | 0.0% | 0.00% | – |
| Q4 2020 | $15,000 | +36.4% | 175 | 0.0% | 0.00% | – |
| Q3 2020 | $11,000 | +57.1% | 175 | 0.0% | 0.00% | – |
| Q2 2020 | $7,000 | +40.0% | 175 | 0.0% | 0.00% | – |
| Q1 2020 | $5,000 | -66.7% | 175 | -14.6% | 0.00% | -100.0% |
| Q4 2019 | $15,000 | – | 205 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |